Investors / United States / Cancer Focus Fund
Cancer Focus Fund
Venture capital · Houston, TX, United States · North America
Cancer Focus Fund is an oncology-focused investment fund established with The University of Texas MD Anderson Cancer Center. It sources cancer drug candidates globally, has its Scientific Advisory Committee of MD Anderson experts review them, and invests in exchange for equity and downstream economics tied to clinical and regulatory success.
Invests inHealthcare & Biotech
In its own wordsoncologybiotechtherapeuticscell therapyimmunotherapyprecision medicine
Your fit with Cancer Focus Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCancer Focus Fund lists 6 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 75% of its companies are based in United States. It invests most often alongside 2b AHEAD Ventures, ADIT Ventures and BioAdvance.
Counts come from funding rounds that name Cancer Focus Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundCancer Focus Fund does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 89th | 17% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| 2b AHEAD Ventures | 1 |
| ADIT Ventures | 1 |
| BioAdvance | 1 |
| Fitz Gate Ventures | 1 |
| KdT Ventures | 1 |
| Mission BioCapital | 1 |
| Modi Ventures | 1 |
| Pontifax | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with 2b AHEAD Ventures
Compare Cancer Focus Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Cancer Focus Fund| Date | Company | Stage |
|---|---|---|
| 18 Feb 2026 | Series A |
Round details for Cancer Focus Fund
Amounts, full round histories and every co-investor in Cancer Focus Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Eisbach Bio is a clinical-stage biotechnology company developing next-generation small-molecule cancer therapies by targeting the activated state of enzymes. | Healthcare & Biotech | Portfolio page | ||
| ImmunoGenesis is engineering next-generation immunotherapies designed for hardest-to-treat tumors. | Healthcare & Biotech | Portfolio page | ||
| Link Cell Therapies is a biotechnology company that develops next-generation CAR-T therapeutics for solid and hematologic cancers | Healthcare & Biotech | Portfolio page | ||
| March.biosciences is a clinical-stage company developing CAR-T cell strategies to address hematological cancers. | Healthcare & Biotech | Portfolio page | ||
| Mereo BioPharma develops therapies for rare diseases | Healthcare & Biotech | Portfolio page | ||
| Starget Pharma is a clinical company developing a new class of Smart Targeted Radioligands for precision oncology of hard-to-heal cancers. | Healthcare & Biotech | Feb 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- cancerfocusfund.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 18 Feb 2026
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Cancer Focus Fund's profile as data
Pull Cancer Focus Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/cancerfocusfund.com
# also
GET /v1/firms/cancerfocusfund.com/portfolio
GET /v1/firms/cancerfocusfund.com/coinvestors
GET /v1/firms/cancerfocusfund.com/news